Download PDF
Klin Monbl Augenheilkd 2020; 237(08): 990-994
DOI: 10.1055/a-1191-1395
Statement

Ergänzende Stellungnahme der DOG, der RG und des BVA zur Therapie der proliferativen diabetischen Retinopathie[*]

Stand November 2019 Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft e. V. (RG), Berufsverband der Augenärzte Deutschlands e. V. (BVA)
› Further Information
Also available at
    Permissions and Reprints

Im Jahr 2015 wurden in der Nationalen VersorgungsLeitlinie „Prävention und Therapie von Netzhautkomplikationen bei Diabetes“ unter anderem Kernaussagen zur Therapie der diabetischen Retinopathie konsentiert [1].

* Diese Leitlinie erscheint auch in der Zeitschrift Der Ophthalmologe, Springer Verlag, Heidelberg.




Publication History

Article published online:
16 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Bundesärztekammer (BÄK); Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie (NVL) Prävention und Therapie von Netzhautkomplikationen bei Diabetes (2. Auflage, 2015). Im Internet (Stand: 17.12.2019): http://www.leitlinien.de/nvl/diabetes/netzhautkomplikationen
    PubMedGoogle Scholar
  • 2 Gross JG, Glassman AR, Liu D. et al. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol 2018; 136: 1138-1148 doi:10.1001/jamaophthalmol.2018.3255
    CrossrefPubMedGoogle Scholar
  • 3 Lang GE, Stahl A, Voegeler J. et al. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy – the PRIDE study. Acta Ophthalmol 2019; DOI: 10.1111/aos.14312.
    CrossrefPubMedGoogle Scholar
  • 4 Sivaprasad S, Prevost AT, Bainbridge J. et al. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open 2015; 5: e8405 doi:10.1136/bmjopen-2015-008405
    CrossrefPubMedGoogle Scholar
  • 5 Gupta MP, Kiss S, Chan RVP. Reversal of retinal vascular leakage and arrest of progressive retinal Nonperfusion with monthly anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy. Retina 2018; 38: e74-e75 doi:10.1097/IAE.0000000000002261
    CrossrefPubMedGoogle Scholar
  • 6 Wykoff CC, Nittala MG, Zhou B. et al. Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: outcomes from the randomized RECOVERY trial. Ophthalmol Retina 2019; 3: 1076-1086 doi:10.1016/j.oret.2019.07.011
    CrossrefPubMedGoogle Scholar
  • 7 Ziemssen F, Roeck D, Marahrens L. et al. Bildgebung der diabetischen Retinopathie. Diabetologe 2018; 14: 557-567
    CrossrefPubMedGoogle Scholar
  • 8 Aiello LP, Odia I, Glassman AR. et al. Comparison of early treatment diabetic retinopathy study standard 7-field imaging with ultrawide-field imaging for determining severity of diabetic retinopathy. JAMA Ophthalmol 2019; 137: 65-73 doi:10.1001/jamaophthalmol.2018.4982
    CrossrefPubMedGoogle Scholar
  • 9 Nicholson L, Ramu J, Chan EW. et al. Retinal nonperfusion characteristics on ultra-widefield angiography in eyes with severe nonproliferative diabetic retinopathy and proliferative diabetic retinopathy. JAMA Ophthalmol 2019; 137: 626-631 doi:10.1001/jamaophthalmol.2019.0440
    CrossrefPubMedGoogle Scholar
  • 10 Ehlers JP, Jiang AC, Boss JD. et al. Quantitative ultra-widefield angiography and diabetic retinopathy severity: an assessment of panretinal leakage index, ischemic index and microaneurysm count. Ophthalmology 2019; 126: 1527-1532 doi:10.1016/j.ophtha.2019.05.034
    CrossrefPubMedGoogle Scholar
  • 11 Couturier A, Rey PA, Erginay A. et al. Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor. Ophthalmology 2019; 126: 1685-1694 doi:10.1016/j.ophtha.2019.06.022
    CrossrefPubMedGoogle Scholar
  • 12 Enders C, Baeurle F, Lang GE. et al. Visualization of retinal neovascularization with optical coherence tomography angiography in comparison with fluorescein angiography. Klin Monatsbl Augenheilkd 2019; 236: 1325-1330 doi:10.1055/a-0983-2271
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Schwartz R, Khalid H, Sivaprasad S. et al. Objective evaluation of proliferative diabetic retinopathy using OCT. Ophthalmol Retina 2019; DOI: 10.1016/j.oret.2019.09.004.
    CrossrefPubMedGoogle Scholar
  • 14 Russell JF, Flynn HW, Sridhar J. et al. Distribution of diabetic neovascularization on ultra-widefield fluorescein angiography and on simulated widefield OCT angiography. Am J Ophthalmol 2019; 207: 110-120 doi:10.1016/j.ajo.2019.05.031
    CrossrefPubMedGoogle Scholar
  • 15 Russell JF, Shi Y, Hinkle JW. et al. Longitudinal wide-field swept-source OCT angiography of neovascularization in proliferative diabetic retinopathy after panretinal photocoagulation. Ophthalmol Retina 2019; 3: 350-361 doi:10.1016/j.oret.2018.11.008
    CrossrefPubMedGoogle Scholar
  • 16 Berufsverband der Augenärzte; Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des diabetischen Makulaödems. Ophthalmologe 2019; DOI: 10.1007/s00347-019-01015-2.
    CrossrefPubMedGoogle Scholar
  • 17 Klein R, Klein BE, Moss SE. et al. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243
    CrossrefPubMedGoogle Scholar
  • 18 Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98 (5 Suppl.): 766-785
    CrossrefPubMedGoogle Scholar
  • 19 Zhou B, Mitchell TC, Rusakevich AM. et al. Noncompliance in prospective retina clinical trials: analysis of factors predicting loss to follow-up. Am J Ophthalmol 2019; DOI: 10.1016/j.ajo.2019.10.012.
    CrossrefPubMedGoogle Scholar
  • 20 Sun JK, Glassman AR, Beaulieu WT. et al. Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology 2019; 126: 87-95
    CrossrefPubMedGoogle Scholar
  • 21 Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized trial. JAMA 2015; 314: 2137-2146 doi:10.1001/jama.2015.15217
    CrossrefPubMedGoogle Scholar
  • 22 Hutton DW, Stein JD, Glassman AR. et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs. panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2019; 24: 1-9 doi:10.1001/jamaophthalmol.2019.4284
    CrossrefPubMedGoogle Scholar
  • 23 Obeid A, Gao X, Ali FS. et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 2018; 125: 1386-1392 doi:10.1016/j.ophtha.2018.02.034
    CrossrefPubMedGoogle Scholar
  • 24 Sun JK, Wang PW, Taylor S. et al. Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of RIDE and RISE studies. Ophthalmology 2019; 126: 712-720 doi:10.1016/j.ophtha.2018.10.041
    CrossrefPubMedGoogle Scholar
  • 25 Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I. et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014; DOI: 10.1002/14651858.CD008721.pub2.
    CrossrefPubMedGoogle Scholar